Quorum Innovations Advances Human Microbiome Program
PRNewswire/Sarasota, FL, October 27, 2016– Quorum Innovations today announced a major milestone that includes a biotherapeutic discovery platform to advance the introduction of new treatments for skin, GI, inflammatory and metabolic conditions utilizing human microbiome biotherapeutics.
Quorum is pleased that the USPTO has recognized the novelty and importance of this biotherapeutic discovery process, which is the cornerstone of this patent. Quorum expects to accelerate development in a new class of biotherapeutics utilizing the human microbiome. Quorum Innovations has successfully isolated a unique series of bacterial-derived bioactive compounds. They protect the human microbiome by simultaneously decreasing disease-causing bacteria while defending and increasing health-promoting bacteria. Quorum has named these compounds – ProBiomic™ Biotherapeutics. Unlike other products on the market today, Quorum bioactives are also sourced from the human microbiome itself, not from foreign sources such as dirt, exotic plants, or animals. It is grown in biofilm form and then processed such that the bioactive compounds contain no live bacteria.
Other unique activities of Quorum Innovations’ ProBiomicTM Biotherapeutics include: reduction of inflammation, promotion of innate immune defenses, upregulation of key tissue structural proteins such as filaggrin in human skin and esophagus, and modulation of critical metabolic control genes. Furthermore, bioactivities and can be formulated in multiple vehicles, including alcohol, aqueous and lipid, have been tested and found to be stable. Unlike most other bacteria which require being kept alive to maintain effect, Quorum Innovation’s bioactives maintains activity even after heat sterilization. These characteristics enable use in a broad range of applications, from direct-to-consumer to pharmaceutical products.
About Quorum Innovations
Dr. Nicholas Monsul, MD, CEO, and Dr. Eva Berkes, MD, Chief Science Officer, founded Quorum Innovations in 2011. Quorum Innovation’s new biotherapeutic candidates are extracted from the human microbiome. This creates a new era in immunology and biotherapeutic discovery. Once delivered, like native human microbiota in healthy individuals, Quorum Innovation’s ProBiomicTM Biotherapeutics act like microbiome-based software to direct human cells to express particular proteins within target tissues. By matching the particular ProBiomicTM Biotherapeutic to the desired protein effect in the chosen organ of interest, our new human microbiome-based biotherapeutics have the power to regulate human and human microbiomial physiology like no other biotherapeutic system today.
Emerging research on various types of inflammation indicate direct links between many clinical conditions and a dysbiotic or abnormal microbiome. Skin inflammation causes skin barrier compromise, leading to conditions such as atopic dermatitis, psoriasis, acne and rosacea. Pharmaceutical and personal care industries are seeking better ways to prevent and treat chronic skin disorders and other inflammatory conditions by addressing the underlying microbiome imbalances associated with these conditions.